Asset profile
BMS-986322
Small molecule
Evidence outlook · lead readout
NCT05730725 · Psoriasis
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT05730725: The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
70 competitors in this universe: 10 direct rivals (same mechanism and indication), 2 same-class, 58 same-indication; 52 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BMS-986322: this drug | Phase 2 | Small molecule | TYK2 | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | ||
| HS-10374 | Phase 3 | Small molecule | TYK2 | ||
| ICP-488 | Phase 3 | Small molecule | TYK2 | ||
| SYHX1901 | Phase 3 | Small molecule | TYK2 | ||
| TQH3906 | Phase 3 | Small molecule | TYK2 | ||
| WD-890 | Phase 3 | Small molecule | TYK2 | ||
| Zasocitinib | Phase 3 | Small molecule | TYK2 | ||
| CMS-D001 | Phase 2/3 | Small molecule | TYK2 | ||
| CS32582 | Phase 1/2 | Small molecule | TYK2 | ||
| D-2570 | Phase 3 | Small molecule | TYK2 | ||
| GLPG3667 | Phase 2 | Small molecule | TYK2 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F |
…and 55 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.